申请人:Egyt Gyogyszervegyeszeti Gyar
公开号:US04423044A1
公开(公告)日:1983-12-27
The invention relates to new 3,4-dihydro-5H-2,3-benzodiazepine derivatives of general formula (I) and pharmaceutically acceptable acid addition salts thereof, ##STR1## wherein R represents a phenyl group optionally carrying one or two substituents selected from the group consisting of halogen, hydroxy, C.sub.1-4 alkoxy and benzyloxy; a furyl or a thienyl group, R.sup.1 stands for a hydrogen atom or a C.sub.1-4 alkyl group, R.sup.2 and R.sup.3 each represent hydrogen atom, C.sub.1-4 alkoxy, C.sub.4-7 cycloalkoxy or benzyloxy group. The new compounds of the general formula (I) can be prepared by reducing a 5H-2,3-benzodiazepine derivative of the general formula (II) ##STR2## wherein R, R.sup.1, R.sup.2 and R.sup.3 have the above-defined meanings, with an inorganic or organic hydride and/or complex metal hydride. The new compounds of the general formula (I) possess significant central nervous effects and can advantageously be used in the therapy.
该发明涉及新的一种3,4-二氢-5H-2,3-苯并二氮䓬啉衍生物,其一般式为(I),及其药学上可接受的酸盐,其中R代表一个苯基,可选地携带来自卤素、羟基、C.sub.1-4烷氧基和苄氧基的一种或两种取代基;一种呋喃基或噻吩基,R.sup.1代表氢原子或C.sub.1-4烷基,R.sup.2和R.sup.3分别代表氢原子、C.sub.1-4烷氧基、C.sub.4-7环烷氧基或苄氧基。一般式(I)的新化合物可以通过将一般式(II)的5H-2,3-苯并二氮䓬啉衍生物还原而制备而得,其中R、R.sup.1、R.sup.2和R.sup.3具有上述定义的含义,所述还原用无机或有机氢化物和/或复合金属氢化物。一般式(I)的新化合物具有显著的中枢神经作用,并可有利地用于治疗。